ACADIA Pharmaceuticals Inc. (LON:0A4W)
London
· Delayed Price · Currency is GBP · Price in USD 18.62
-0.02 (-0.11%)
At close: Jan 31, 2025
ACADIA Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 957.8 | 726.44 | 517.24 | 484.15 | 441.76 | Upgrade
|
| Revenue Growth (YoY) | 31.85% | 40.45% | 6.83% | 9.60% | 30.28% | Upgrade
|
| Cost of Revenue | 385.09 | 393.26 | 371.74 | 258.56 | 286.88 | Upgrade
|
| Gross Profit | 572.71 | 333.18 | 145.49 | 225.59 | 154.88 | Upgrade
|
| Selling, General & Admin | 488.43 | 406.56 | 369.09 | 396.03 | 388.66 | Upgrade
|
| Operating Expenses | 488.43 | 406.56 | 369.09 | 396.03 | 388.66 | Upgrade
|
| Operating Income | 84.28 | -73.38 | -223.6 | -170.44 | -233.79 | Upgrade
|
| Interest & Investment Income | 25.46 | 17.23 | 6.61 | 0.59 | 6.61 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.82 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 111.56 | -56.15 | -216.99 | -169.85 | -227.18 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -52.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 5.11 | 3.54 | 2.33 | -1 | Upgrade
|
| Gain (Loss) on Sale of Assets | 146.52 | - | - | - | - | Upgrade
|
| Pretax Income | 258.08 | -51.04 | -213.44 | -167.52 | -280.97 | Upgrade
|
| Income Tax Expense | 31.62 | 10.25 | 2.53 | 0.35 | 0.61 | Upgrade
|
| Net Income | 226.45 | -61.29 | -215.98 | -167.87 | -281.58 | Upgrade
|
| Net Income to Common | 226.45 | -61.29 | -215.98 | -167.87 | -281.58 | Upgrade
|
| Shares Outstanding (Basic) | 166 | 164 | 162 | 160 | 157 | Upgrade
|
| Shares Outstanding (Diluted) | 166 | 164 | 162 | 160 | 157 | Upgrade
|
| Shares Change (YoY) | 1.55% | 1.32% | 0.74% | 2.01% | 6.88% | Upgrade
|
| EPS (Basic) | 1.37 | -0.37 | -1.34 | -1.05 | -1.79 | Upgrade
|
| EPS (Diluted) | 1.36 | -0.37 | -1.34 | -1.05 | -1.79 | Upgrade
|
| Free Cash Flow | 157.2 | 16.65 | -114.04 | -126.78 | -143.75 | Upgrade
|
| Free Cash Flow Per Share | 0.94 | 0.10 | -0.71 | -0.79 | -0.91 | Upgrade
|
| Gross Margin | 59.79% | 45.86% | 28.13% | 46.60% | 35.06% | Upgrade
|
| Operating Margin | 8.80% | -10.10% | -43.23% | -35.20% | -52.92% | Upgrade
|
| Profit Margin | 23.64% | -8.44% | -41.76% | -34.67% | -63.74% | Upgrade
|
| Free Cash Flow Margin | 16.41% | 2.29% | -22.05% | -26.19% | -32.54% | Upgrade
|
| EBITDA | 100.16 | -67.83 | -221.57 | -167.1 | -230.85 | Upgrade
|
| EBITDA Margin | 10.46% | -9.34% | -42.84% | -34.51% | -52.26% | Upgrade
|
| D&A For EBITDA | 15.88 | 5.55 | 2.03 | 3.34 | 2.93 | Upgrade
|
| EBIT | 84.28 | -73.38 | -223.6 | -170.44 | -233.79 | Upgrade
|
| EBIT Margin | 8.80% | -10.10% | -43.23% | -35.20% | -52.92% | Upgrade
|
| Effective Tax Rate | 12.25% | - | - | - | - | Upgrade
|
| Revenue as Reported | 957.8 | 726.44 | 517.24 | 484.15 | 441.76 | Upgrade
|
| Advertising Expenses | 21.1 | 9.4 | 5.5 | 41.8 | 51.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.